Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

NCT05159193 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

372

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: pegylated liposomal doxorubicin (PLD)
DRUG: cyclophosphamide (C)
DRUG: trastuzumab (H)
DRUG: pertuzumab (P)
DRUG: docetaxel (T)
DRUG: docetaxel (T)
DRUG: carboplatin (Cb)
DRUG: trastuzumab (H)
DRUG: pertuzumab (P)

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Collaborators

[object Object]